Skip to main content
TipRanks
Go Ultimate75% OFF

Thyrocare Technologies Ltd (THYROCARE) AI Stock Analysis

4 Followers
IN:THYROCARE

Thyrocare Technologies Ltd

(NSE:THYROCARE)

Select Model
Rating:58Neutral
Price Target:INR 527.00â–²(4.37% Upside)
Action:reiterated
Date:10/31/26

Thyrocare scores moderately. Its greatest strength is financial health: a near debt-free balance sheet, ~78% equity-to-asset ratio, a projected ~27.8% ROE and robust free cash flow of ₹1.95B backed by cash conversion above 1.0x net income. Offsetting this, the stock is in a well-defined downtrend — trading below all key moving averages with negative MACD and subdued RSI — and valuation is rich at a 50.4x P/E given only ~8.7% revenue growth and margins still materially below FY2022 peaks. A ~2.04% dividend yield and improving profitability trend provide partial support, but weak price momentum and premium pricing cap the score. Earnings call and corporate event components were excluded due to insufficient data, with their weight redistributed across the remaining factors.

Positive Factors
Conservative balance sheetVery low leverage gives Thyrocare financial flexibility to fund laboratory capacity, technology, and network expansion without heavy reliance on borrowing. The strong equity base also improves resilience if diagnostic volumes or profitability weaken during the next several quarters.
Negative Factors
Margin volatilitySharp historical margin swings make current profitability less predictable and weaken confidence that recent margins will persist unchanged. Variability can complicate planning, reduce the reliability of earnings growth, and limit how much of today’s profit can be treated as durable.

Thyrocare Technologies Ltd (THYROCARE) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%40%IN:THYROCARE+4.62%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 77.24B
Dividend Yield
1.85%
Average Volume (3M)
65.73K
Price to Earnings (P/E)
55.6
Beta (1Y)
0.67
Revenue Growth
21.99%
EPS Growth
12.77%
Country
India
Employees
2,092
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Thyrocare Technologies Ltd Business Overview & Revenue Model

Company Description

Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across th...

How the Company Makes Money

Thyrocare primarily makes money by providing diagnostic testing services and earning fees per test or test package processed through its laboratory network. Revenue is generated from (1) individual diagnostic tests and (2) bundled health-check and we...

Thyrocare Technologies Ltd Financial Statement Overview

Summary

A strong balance sheet (score 78) and high-quality cash generation (score 74) anchor the fundamentals: debt-to-equity remains minimal at ~0.087, equity-to-assets is ~78%, ROE is projected to rebound to ~27.8%, and FY2026 free cash flow of ₹1.95B represents ~75% growth with operating cash flow consistently exceeding net income. The income statement (score 62) is the weaker link — revenue growth of ~8.7% in FY2026 follows a flat FY2025 and a ~10.6% decline in FY2023, while net margin (~19.7%) and EBITDA margin (~31.6%) remain well below FY2022 COVID-era peaks, with notable gross margin volatility. Overall, a capital-efficient, low-leverage business on a recovery path but not yet back to peak profitability.

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue9.30B8.29B6.87B5.72B5.27B5.89B
Gross Profit5.35B3.10B4.96B1.81B3.63B4.19B
EBITDA2.63B2.65B2.04B1.48B1.31B2.64B
Net Income1.44B1.63B915.10M707.60M644.90M1.76B
Balance Sheet
Total Assets7.25B7.47B6.93B6.44B6.33B6.08B
Cash, Cash Equivalents and Short-Term Investments2.06B2.31B1.92B1.77B1.51B1.39B
Total Debt568.80M506.90M246.80M423.40M233.10M207.00M
Total Liabilities1.73B1.61B1.46B1.16B975.00M810.90M
Stockholders Equity5.53B5.86B5.47B5.27B5.34B5.27B
Cash Flow
Free Cash Flow01.95B1.46B1.06B856.60M755.80M
Operating Cash Flow02.16B1.91B1.68B1.29B1.13B
Investing Cash Flow0-260.80M-525.20M-912.80M-389.90M-235.70M
Financing Cash Flow0-1.70B-1.30B-848.00M-861.80M-894.10M

Thyrocare Technologies Ltd Technical Analysis

Technical Analysis SentimentPositive
Last Price504.95

Price Trends

50DMA517.72Negative
100DMA544.93Negative
200DMA485.92Positive

Market Momentum

MACD-2.97Negative
RSI51.54Neutral
STOCH80.08Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Positive. The current price of 504.95 is above the 20-day moving average (MA) of 486.96, below the 50-day MA of 517.72, and above the 200-day MA of 485.92, indicating a neutral trend. The MACD of -2.97 indicates Negative momentum. The RSI at 51.54 is Neutral, neither overbought nor oversold. The STOCH value of 80.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:THYROCARE.

Thyrocare Technologies Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:THYROCARE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:LALPATHLABIN:LALPATHLAB82OutperformINR 329.76B56.34―0.89%16.71%9.15%
IN:METROPOLISIN:METROPOLIS71OutperformINR 117.63B52.15―0.35%19.84%41.41%
IN:KRSNAAIN:KRSNAA70OutperformINR 16.56B16.91―0.39%15.90%15.67%
IN:VIMTALABSIN:VIMTALABS69NeutralINR 20.84B25.92―0.43%11.77%1.69%
IN:VIJAYAIN:VIJAYA67NeutralINR 158.21B77.49―0.13%24.47%34.25%
IN:THYROCAREIN:THYROCARE58NeutralINR 80.13B55.65―1.85%21.99%12.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%40%IN:THYROCAREIN:KRSNAAIN:LALPATHLABIN:METROPOLISIN:VIJAYAIN:VIMTALABSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:THYROCARE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:THYROCAREThyrocare Technologies Ltd504.952.200.44%
IN:KRSNAAKrsnaa Diagnostics Limited514.40-297.15-36.62%
IN:LALPATHLABDr. Lal PathLabs Limited1962.15406.9326.17%
IN:METROPOLISMetropolis Healthcare Ltd.558.6072.2114.84%
IN:VIJAYAVijaya Diagnostic Centre Ltd.1511.95505.7550.26%
IN:VIMTALABSVimta Labs Limited471.10-137.61-22.61%

Thyrocare Technologies Ltd Corporate Events

Thyrocare Plans October 29 Call on Q2 FY2026-27 Results

Oct 22, 2026

Thyrocare Technologies Ltd has scheduled an earnings conference call for analysts and investors to discuss its unaudited financial results for the quarter and half year ended September 30, 2026. The call will be held on Thursday, October 29, 2026, at...

Thyrocare publishes postal ballot notice and opens e‑voting for shareholders

Sep 29, 2026

Thyrocare Technologies Ltd has notified the stock exchanges that it has published its postal ballot notice in English and Marathi newspapers, confirming that the ballot documents have been dispatched and providing details of the e‑voting period. The...

Thyrocare exits radiology arm with Rs 141 crore sale to Trovera

Sep 21, 2026

Thyrocare Technologies Ltd has approved the sale of its entire shareholding in Nueclear Healthcare Ltd, its material wholly owned subsidiary operating the radiology and diagnostic imaging business, to Trovera Healthcare Pvt Ltd for a total considerat...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026